104 related articles for article (PubMed ID: 14561851)
1. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension.
Ju H; Behm DJ; Nerurkar S; Eybye ME; Haimbach RE; Olzinski AR; Douglas SA; Willette RN
J Pharmacol Exp Ther; 2003 Dec; 307(3):932-8. PubMed ID: 14561851
[TBL] [Abstract][Full Text] [Related]
2. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging.
Lenhard SC; Nerurkar SS; Schaeffer TR; Mirabile RC; Boyce RW; Adams DF; Jucker BM; Willette RN
J Pharmacol Exp Ther; 2003 Dec; 307(3):939-46. PubMed ID: 14561850
[TBL] [Abstract][Full Text] [Related]
3. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection.
Olzinski AR; McCafferty TA; Zhao SQ; Behm DJ; Eybye ME; Maniscalco K; Bentley R; Frazier KS; Milliner CM; Mirabile RC; Coatney RW; Willette RN
Cardiovasc Res; 2005 Apr; 66(1):170-8. PubMed ID: 15769460
[TBL] [Abstract][Full Text] [Related]
4. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
Bao W; Behm DJ; Nerurkar SS; Ao Z; Bentley R; Mirabile RC; Johns DG; Woods TN; Doe CP; Coatney RW; Ohlstein JF; Douglas SA; Willette RN; Yue TL
J Cardiovasc Pharmacol; 2007 Jun; 49(6):362-8. PubMed ID: 17577100
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
Willette RN; Eybye ME; Olzinski AR; Behm DJ; Aiyar N; Maniscalco K; Bentley RG; Coatney RW; Zhao S; Westfall TD; Doe CP
J Pharmacol Exp Ther; 2009 Sep; 330(3):964-70. PubMed ID: 19556450
[TBL] [Abstract][Full Text] [Related]
6. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction.
Behr TM; Nerurkar SS; Nelson AH; Coatney RW; Woods TN; Sulpizio A; Chandra S; Brooks DP; Kumar S; Lee JC; Ohlstein EH; Angermann CE; Adams JL; Sisko J; Sackner-Bernstein JD; Willette RN
Circulation; 2001 Sep; 104(11):1292-8. PubMed ID: 11551882
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent.
Widder J; Behr T; Fraccarollo D; Hu K; Galuppo P; Tas P; Angermann CE; Ertl G; Bauersachs J
Cardiovasc Res; 2004 Jul; 63(1):161-7. PubMed ID: 15194473
[TBL] [Abstract][Full Text] [Related]
8. Chronic treatment of DA-8159, a new phosphodiesterase type V inhibitor, attenuates endothelial dysfunction in stroke-prone spontaneously hypertensive rat.
Choi SM; Kim JE; Kang KK
Life Sci; 2006 Feb; 78(11):1211-6. PubMed ID: 16214180
[TBL] [Abstract][Full Text] [Related]
9. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
10. Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase-2 upregulation: implications on hypertension.
Wong WT; Tian XY; Chen Y; Leung FP; Liu L; Lee HK; Ng CF; Xu A; Yao X; Vanhoutte PM; Tipoe GL; Huang Y
Circ Res; 2010 Oct; 107(8):984-91. PubMed ID: 20724703
[TBL] [Abstract][Full Text] [Related]
11. P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1.
Nerurkar SS; Olzinski AR; Frazier KS; Mirabile RC; O'Brien SP; Jing J; Rajagopalan D; Yue TL; Willette RN
Biomarkers; 2007; 12(1):87-112. PubMed ID: 17438656
[TBL] [Abstract][Full Text] [Related]
12. Modulation of endotoxin-induced endothelial function by calcium/calmodulin-dependent protein kinase.
Cuschieri J; Gourlay D; Garcia I; Jelacic S; Maier RV
Shock; 2003 Aug; 20(2):176-82. PubMed ID: 12865664
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha up-regulates the expression of CCL2 and adhesion molecules of human proximal tubular epithelial cells through MAPK signaling pathways.
Ho AW; Wong CK; Lam CW
Immunobiology; 2008; 213(7):533-44. PubMed ID: 18656701
[TBL] [Abstract][Full Text] [Related]
14. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
[TBL] [Abstract][Full Text] [Related]
15. Role of p38 MAPK in ICAM-1 expression of vascular endothelial cells induced by lipopolysaccharide.
Yan W; Zhao K; Jiang Y; Huang Q; Wang J; Kan W; Wang S
Shock; 2002 May; 17(5):433-8. PubMed ID: 12022767
[TBL] [Abstract][Full Text] [Related]
16. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
Barone FC; Irving EA; Ray AM; Lee JC; Kassis S; Kumar S; Badger AM; White RF; McVey MJ; Legos JJ; Erhardt JA; Nelson AH; Ohlstein EH; Hunter AJ; Ward K; Smith BR; Adams JL; Parsons AA
J Pharmacol Exp Ther; 2001 Feb; 296(2):312-21. PubMed ID: 11160612
[TBL] [Abstract][Full Text] [Related]
17. Death-associated protein kinase 3 mediates vascular inflammation and development of hypertension in spontaneously hypertensive rats.
Usui T; Okada M; Hara Y; Yamawaki H
Hypertension; 2012 Oct; 60(4):1031-9. PubMed ID: 22868392
[TBL] [Abstract][Full Text] [Related]
18. Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury.
Ju H; Nerurkar S; Sauermelch CF; Olzinski AR; Mirabile R; Zimmerman D; Lee JC; Adams J; Sisko J; Berova M; Willette RN
J Pharmacol Exp Ther; 2002 Apr; 301(1):15-20. PubMed ID: 11907152
[TBL] [Abstract][Full Text] [Related]
19. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation.
Gao F; Yue TL; Shi DW; Christopher TA; Lopez BL; Ohlstein EH; Barone FC; Ma XL
Cardiovasc Res; 2002 Feb; 53(2):414-22. PubMed ID: 11827692
[TBL] [Abstract][Full Text] [Related]
20. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.
Underwood DC; Osborn RR; Bochnowicz S; Webb EF; Rieman DJ; Lee JC; Romanic AM; Adams JL; Hay DW; Griswold DE
Am J Physiol Lung Cell Mol Physiol; 2000 Nov; 279(5):L895-902. PubMed ID: 11053025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
